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The value of measuring quality of life has been increasingly
recognised. It should identify and better describe the
damaging effects of the disease or its treatment. This should
help the physician and the patient to choose more easily
between alternative treatment options. In controlled clinical
trials, direct measurement of quality of life is an important
outcome measure. When there are no differences in survival
it will be possible to recommend a treatment which produces
the best quality of life. However, if one treatment produces
satisfactory quality of life but unsatisfactory survival then
very difficult value judgements are likely to remain whatever
methods for measurement are developed.
Interest in measuring quality of life has increased during
the 1980s. In 1978, Bardelli and Saracci reported that less
than 5% of papers in major cancer journals measured any
aspect of quality of life. Since then there has been a major
increase, perhaps reflecting the increasing recognition of the
limitations and potential hazards of modern cancer treat-
ment and changes in social attitudes. Reviews of this field
have been conducted by Fayers & Jones (1983), Holland
(1984), De Haes & Van Knippenberg (1985), Ventafridda et
al. (1986), Clark & Fallowfield (1986), Selby & Robertson
(1987), McDowell & Newell (1987) and Walker & Rosser
(1988).
The widespread feeling that quality bf life should be
measured in clinical trials has led to requests for guidance
from the Cancer Therapy Committee of the Medical
Research Council and other bodies as to the best available
methods at present. The Working Party was convened to
review existing measures of quality of life in patients with
cancer and advise the Cancer Therapy Committee about
their use within clinical trials and thus provide a source of
advice for all clinical trialists.
1. Background
We agreed to a pragmatic approach to quality of life and
decided that assessment would cover these dimensions:
symptoms due to cancer; adverse effects of treatmeant;
physical functioning; social interaction; psychological adjust-
ment; sexual functioning; and body image. Any measure
recommended must be capable of assessing one or more of
these dimensions in a reliable and valid way and be able to
be completed by the patient within 10 minutes, be easy to
administer, easy to score and reflect changes over time.
We recognised that no scale would fulfil the needs of all
clinical trials. So, we would try to recommend core question-
naires which could be applicable to most trials. Additional
items could then be added to reflect specific diseases or
treatments. We acknowledged that clinicians wanted scales
which were short and simple but were concerned that these
might be incapable of measuring quality of life in a valid
and reliable way. We recognised that general instruments
already existed which purported to measure the impact of
physical illness (like the Nottingham Health Profile
(McEwen, 1988) and Sickness Impact Profile (Bergner,
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1988)) but considered that they had not been calibrated in
cancer patients. The clinical relevance of scores on these
scales was, therefore, difficult to interpret and the instru-
ments are lengthy.
2. Assessment criteria
We agreed on a set of key questions to permit detailed
assessment of available instruments.
(a) Function
(i)
(ii)
Is it designed for use with specific or different types
of cancer?
Which dimensions of quality of life does it measure?
(b) Format
(i) How many items does it contain?
(ii) How well laid out are they?
(iii) Does it employ a linear analogue, categorical or other
method of scaling?
(iv) Are there alternative forms?
(v) What time period does it cover (e.g. the past few days
or last month).
(vi) Does it require patients to refer to their own baseline
(e.g. 'no more than usual' to 'very much more than
usual') or to absolute levels ('not at all' to 'very
much').
(c) Administration
(i) How easy is it to administer?
(ii) Is training needed?
(iii) How long does it take to complete?
(iv) Are all the items easily understood by patients?
(v) Are all the items acceptable or do any cause distress?
(vi) Can the questionnaire/scale be administered by
computer?
(d) Scoring
(i) How easy is it to score?
(ii) What scores does it generate (e.g. an overall score,
scores on specific sub-scales, scores on each item)?
(iii) Do population norms exist?
(iv) How easy is it to analyse the responses statistically?
(e) Structure
(i) How were the items within the questionnaire/scale
obtained (e.g. did they come from interviews with
patients, relatives, health professionals, or existing
scales)?
(ii) Do the items form discrete sub-scales?
(iii) Are the sub-scales based on factor analysis of the
items?
(iv) Has the factor structure been replicated? With what
results?
(v) Do the items which load highly on one sub-scale
load on others?
(vi) How much does each item contribute to the overall
score?
(vii) Are shorter forms available?
(f) Clinical usage
(i) Which patient groups have completed the question-
naire?
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(ii)
(iii)
Has it been used to measure change over time? (At
what time intervals? With what response rate?)
Has it been used in clinical trials?
(g) Reliability
(i)
(ii)
(iii)
(iv)
Has test-retest reliability been evaluated?
Has the self-rating version been compared with an
observer rating version?
Has it been compared with other quality of life
measures?
Are data on split-half reliability available?
(h) Validity
(i) Does the questionnaire/scale measure accurately:
Changes over time.
Differences between groups:
by stage of disease
by mode of treatment.
(ii) How well does it correlate with the findings of trained
interviewers who administer standardised interviews
to assess physical, social and psychological
functioning (i.e. a 'gold standard' assessment)?
3. Instruments assessed
These included:
(a) Global measures
(i) Gough's visual analogue scale (Gough et al., 1983).
(ii) Rosser and Kind's distress/disability matrix (Rosser &
Kind, 1978).
(iii) Quality of life adjusted years (QUALYS) (Williams,
1985).
(b) Performance indices
(i) Karnofsky et al. (1948).
(ii) ECOG, Eastern Co-operative Oncology Group
(Zubrod et al., 1960).
(iii) Katz activities of daily living (Katz & Akbom, 1976).
(iv) World Health Organization scales (WHO, 1979).
(c) Scales measuring several dimensions
(i)
(ii)
(iii)
(iv)
(v)
(vi)
(vii)
(viii)
Iszak and Medalie index (1971).
Priestman and Baum (1976) linear self assessment
system.
Functional living index for cancer (Schipper et al.,
1984).
Ontario Cancer Institute quality of life questionnaire
(Selby et al., 1984).
Padilla QL questionnaire (Padilla et al., 1981).
QL index (Spitzer et al., 1981).
EORTC QL questionnaire (Aaronson et al., 1986).
Rotterdam symptom check list (Haes et al., 1986).
(d) Psychological dimension
(i)
(ii)
Hospital anxiety and depression scale (Zigmong &
Snaith, 1983).
General health questionnaire (Goldberg & Hillier,
1979).
4. Mode of assessment
Each questionnaire/scale was assessed independently by at
least two members of the working party using the agreed
criteria and relevant literature. These assessments were
circulated to the remaining members of the working party
and then discussed to determine the relative advantages and
disadvantages of each measure.
5. Main comments
(a) Global measures
(i) Gough's scale. Patients are required to rate a 10cm line
in terms of 'How would you rate your feeling of well-being
today?' The authors argue that it performs as well as more
complex scales (The Spitzer QL index (objective and
subjective versions), Baum and Priestman LASA system).
This conclusion is erroneous since it is based on an over-
reliance on correlation coefficients and a failure to examine
areas of significant disagreement between different measures.
No data are given about how well this scale measures
changes over time. Nor does this global rating of well-being
give information about the relative contributions of the
component dimensions. It was not considered a serious
contender despite its simplicity.
(ii) Rosser and Kind's disability/distress matrix. This
method requires patients with physical or psychiatric illness
and health care professionals to evaluate 29 combinations of
disability (O=no disability to 8=unconscious) and distress
(no to severe distress). It involves a lengthy interview of
between I' and 4 hours, which is acknowledged to be
'potentially distressing and traumatic'. Scores are presented
as group medians and there is no interest in the scores of
individual patients since this measure seeks to determine a
consensus view of the relative importance of differing states
of disability and distress. While data about such views could
inform decisions about priorities within health care they do
not enable quality of life to be measured within clinical
trials.
(iii) Quality of life adjusted years index (QUALYS). This
measure is designed to take account of the quality as well as
the duration of survival in assessing the outcome of health
care procedures and services. Unfortunately, the judgements
on which it rests are drawn from small samples of respon-
dents who were chosen arbitrarily. There is no evidence that
these judgements bear much relationship to real judgements
made by patients with cancer when facing decisions about
the utility of different treatments set against the possible
adverse effects on their lives. Thus, it is not known what the
trade-offs would need to be in terms of change in quality of
life before a patient or clinician elected to undergo or reject
a given treatment.
While the QUALY index is important conceptually and
could be used to compare different treatments within a trial,
work is needed to determine the judgements of real patients
in real predicaments.
Meanwhile, the concept is already being misapplied and
abused. For example, clinicians are being asked to justify a
new cancer drug on the basis of the QUALY index without
any attempt to obtain the relevant data from patients and
relatives.
(b) Indices ofphysical performance
(i) Karnofsky index. The Karnofsky index is a valid if
crude predictor of survival. It emphasises physical perfor-
mance and dependency. Scores are weighted heavily on the
physical dimensions of quality of life. Consequently,
Karnofsky scores can give a misleading picture of the social
and psychological dimensions. It has limited reliability in
routine clinical application. While its accuracy in measuring
performance can be improved by training the assessors this
would still fail to measure quality of life adequately, particu-
larly variation in psychological status.
(ii) ECOG. This provides a five-point scale of performance
in contrast to the 10-point Karnofsky scale. It is simple to
use and has a precise but narrow function. It is less easy to
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(iii) WHO scale. This measures physical performance on a
five-point scale. It is easy to use and interpret but has a
limited function.
(c) Scales measuring several dimensions
(i) Iszack and Medalie ability index. This provides a series
of simple rating scales to measure physical, social and
psychological variables. These are tailored to specific cancers
and treatments and are not generalisable across different
cancers or different treatments. They seem of most use in
helping clinicians assess rehabilitation needs and monitoring
outcome in relation to specific cancers.
(ii) Baum and Priestman LASA system. Their set of linear
analogue scales originally covered 10 aspects: well being,
mood, activity, pain, nausea, appetite, housework, social
activity, anxiety and help from treatment. It has been used in
patients with cancer of the breast and appears of most value
in picking up strong treatment effects over time. They
expanded the scale to 25 items and included more relating to
psychological aspects. It has not been compared with other
QL methods or with gold standard interviews. Consequently,
its validity and reliability have still to be determined. But it
seems to detect change over time and to distinguish between
different treatments.
(iii) Functional living index for cancer. The FLIC includes
22 items covering physical symptoms, mood, physical
activity, work, and social interaction. Items are presented in
a linear analogue format. Each line is divided into seven and
covers 'now' or the 'past two weeks'. The items derive from
a pool suggested by a panel of patients and health pro-
fessionals involved in cancer care. The index consists of a
number of sub-scales which are derived from factor analysis
and have been replicated. It is easy to use, administer and
score. It has been validated in a cross-sectional study of
patients with different stages of cancer and on different
treatments.
The word cancer is used in several items and has dis-
tressed patients. Validity has been tested only by comparing
different groups and by correlation with other self-rating
instruments. Performance in detecting changes over time has
yet to be assessed. Nor has it been assessed or calibrated
against 'gold standard' interviews. Consequently, scores on
the component sub-scales are difficult to interpret. There are
so few items on each dimension that its ability to measure
significant changes over time may be poor. For example, few
physical symptoms are included.
These factors prevented the working party from recom-
mending its use in clinical trials despite the attractiveness of
simplicity and ease of use.
(iv) Ontario Cancer Institute quality of life scale. The OCI
scale comprises 32 linear analogue items which cover all the
required dimensions. They are derived from the sickness
impact profile and items relating to specific cancer sites. It is
easy to use, understand and score. It distinguishes well
between patients with breast cancer who are on different
treatments and are at different stages of their disease. But
the author feels that while it is useful in a research context it
is not yet ready for use in clinical trials. It has not been
tested in other patients except those with cancer of the
ovary. The factor structure has still to be replicated.
(v) Padilla QL scale. This is a short 14 item scale contain-
ing three sub-scales. It covers the 'present time' and takes
less than 5 minutes to administer. It is easy to score.
Unfortunately, data on reliability and validity are lacking
and there are too few items to reflect changes on key
dimensions. It appears inferior to the FLIC and OCI Scales.
Linear analogue scales in general can be used to map out
differences between different illnesses but are most valid in
monitoring the impact of treatment regimes over time. They
can tap all dimensions, are simple to administer and score.
However, the time periods covered are often unstated or
vague. It is difficult to interpret the clinical significance of
the scores. Parametric methods of statistical analyses are
suspect. There is no evidence that they are superior to
categorical rating methods.
(vi) Spitzer QL index. This index measures five areas,
including physical activity, daily living, perception of own
health, support from family and friends, and outlook on life.
The scores are summed to produce an overall score of
quality of life. It has the attraction of being simple, easy and
quick to administer. It is available in clinician and patient
rated versions. It was carefully developed by reference to
patients with cancer, patients suffering from other chronic
diseases, their relatives, people who were free of disease,
doctors, nurses and social workers. Unfortunately, the reduc-
tion to five aspects of quality of life reflects an over-reliance
on correlations between the different items that go up to
make each dimension. Consequently it does not do justice to
the different aspects of quality of life. Nor is there evidence
that this index has yet been used successfully within clinical
trials to reflect change over time. Recent studies have found
a poor correlation between the clinician and patient rated
versions. They have suggested that the overall score is
unduly affected by clinicians' judgements about the extent of
the cancer and associated physical disability.
(vii) EORTC questionnaire. This questionnaire was
designed for heterogeneous groups of cancer patients. It
seeks to measure key dimensions, including symptoms of
disease, side-effects of treatment, physical functioning,
psychological distress, social interaction, sexuality, body
image and satisfaction with medical care. It is a self adminis-
tered scale and the format varies according to the dimension
being addressed. Items on physical activity comprise 'yes or
no' responses whereas questions on symptoms use a categori-
cal form asking for answers ranging from 'not at all' to 'very
much'. The checklist of symptoms assessed varies according
to the type of cancer being studied. It is designed for
administration by a nurse within clinics and takes up to 10
minutes to complete. It is easy to score and produces both
an overall score and scores on each sub-scale. Unfortunately
norms do not yet exist but work is underway to establish
norms and check reliability and validity.
While the scale was carefully developed on the basis of
existing measures, its reliability and validity have yet to be
properly assessed. It has still to be checked against 'gold
standard' interviews to see how well it performs. The sub-
scales and factor structure have yet to be replicated. Thus,
although it is promising it is still being developed and is
probably not ready for inclusion in large scale clinical trials.
Initial feedback suggests that the acceptance rate is variable
(ranging between 33 and 90%) but it appears to reflect
changes over time as well as differences between different
diseases and treatments. A major validation study is under-
way to address the questions of how well it performs within
major clinical trials.
(viii) The Rotterdam symptom checklist. This was carefully
derived from a pool of items based on existing question-
naires, together with checklists from interviews with cancer
patients.
It comprises 38 items and each item is rated on a four-
point scale (O=not at all, 3=very much). It is well laid out
and asks respondents to indicate how much they have
experienced particular symptoms over the last week. It is
readily administered by nurses and takes 5-10 minutes to
complete. All items appear understandable and acceptable. It
is easy to score and produces distinct sub-scale scores.
It provides two main sub-scales measuring physical and
psychological dimensions. It is considered to be a good, clear440 P. MAGUIRE & P. SELBY
and simple questionnaire which has been validated against
independent interviews and found to have high sensitivity
and specificity in measuring the psychological dimensions. It
has been used successfully within busy clinics and seems as
effective in advanced cancer patients as in patients with early
disease. It seems to measure physical and social dimensions
equally well but this requires confirmation.
(d) Psychological dimension
(i) Hospital anxiety and depression scale. This 14-item scale
has the advantage that it was developed for patients with
physical disease and excluded items like tiredness that could
be both due to mood disturbance and physical illness. Of the
14 items seven are concerned with anxiety and seven with
depression. It is completed by patients and is easy and quick
to administer. It has proved capable of measuring change
over time within different groups of cancer patients. Recent
studies have suggested that a cut-off point of 10/11 dis-
tinguishes between patients who are coping well with their
cancer and those who have developed morbid anxiety or
depression.
It therefore seems a useful tool for measuring the psycho-
logical dimensions of quality of life in cancer patients.
(ii) General health questionnaire. This 28-item version
includes four sub-scales which measure anxiety, depression,
social functioning and physical symptoms. Preliminary evi-
dence suggests that it works less well with cancer patients
than those who are free of illness in detecting change over
time and determining probable cases of anxiety. It has lower
sensitivity and specificity than the more easily administered
hospital anxiety and depression scale and Rotterdam symp-
tom check list.
Conclusions
1. The current 'best-bet' for tapping key dimensions of
quality of life is the Rotterdam symptom checklist.
Work is ongoing to check further its performance in
patients with different stages of cancer and on different
treatments.
2. When additional items are needed to assess illness or
treatment related variables which are not covered by
the RSCL these can be added in categorical form.
3. The hospital anxiety and depression scale appears
particularly useful in assessing levels of anxiety and
depression in cancer patients.
4. Linear analogue systems (see Priestman & Baum, 1976;
Selby et al., 1984) are useful in highlighting major
differences between treatment regimes in respect of
adverse effects and disease response but clinical inter-
pretation of scores is difficult.
5. A multi-dimensional scale which is specific to patients
with cancer, meets all the assessment criteria and
provides scores which have relevance to clinical judge-
ment remains to be developed. This could be done in
three phases:
(i) In-depth interviews with a representative sample
of cancer patients to determine which aspects of
quality of life most concern them and change for
the better or worse over time.
(ii) The construction of a categorical self-rating
questionnaire which measures the most salient
aspects of quality of life in a way which reflects
both clinically relevant changes and changes
which concern the patient.
(iii) Validation of this questionnaire cross-sectionally
and over time against independent in-depth
assessments by trained interviewers.
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